1. Home
  2. MRLN vs IMUX Comparison

MRLN vs IMUX Comparison

Compare MRLN & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Merlin Inc. Common Stock

MRLN

Merlin Inc. Common Stock

HOLD

Current Price

$0.87

Market Cap

172.8M

Sector

Technology

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$7.17

Market Cap

155.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRLN
IMUX
Founded
2018
2016
Country
United States
United States
Employees
N/A
66
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
172.8M
155.8M
IPO Year
2024
2013

Fundamental Metrics

Financial Performance
Metric
MRLN
IMUX
Price
$0.87
$7.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
13
Target Price
$7.92
★ $43.09
AVG Volume (30 Days)
★ 2.5M
381.9K
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 38.00
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
$9.23
N/A
Revenue Next Year
$153.29
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.82
$0.51
52 Week High
$17.00
$17.43

Technical Indicators

Market Signals
Indicator
MRLN
IMUX
Relative Strength Index (RSI) 21.28 34.46
Support Level N/A $6.35
Resistance Level $3.45 $8.60
Average True Range (ATR) 0.12 0.65
MACD 0.02 0.19
Stochastic Oscillator 7.46 36.89

Price Performance

Historical Comparison
MRLN
IMUX

About MRLN Merlin Inc. Common Stock

Merlin Inc develops software that fulfills the functions of a human pilot in self-flying aircraft to enable both reduced crew and unmanned flight. This technology is designed to be scalable and adaptable across different aircraft types for a growing range of aircraft platforms. The company's aircraft-agnostic, AI-powered software is purpose-built for military and civil programs, and is powering an expanding range of missions and aircraft, through hundreds of autonomous flights from test facilities across the globe. It operates as a single operating and reportable segment.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: